Actionable news
All posts from Actionable news
Actionable news in JNJ: JOHNSON & JOHNSON,

JNJ Earnings: Could Industry Pricing Debate Upstage Quarterly Performance

JNJ issues its latest quarterly performance in the pre-bell hours on Tuesday.

Analysts forecast an average $1.45 per share in profit on topline sales of $17.48 billion.

JNJ has had a three-year history of outpacing Wall Street’s profit expectations.

The constant scrutiny over the costs that big pharmaceutical companies charge for everyday and specialty drugs will likely be getting a closer look within Q3 earnings results due out starting this week and throughout the next month. That's because Congress and presidential hopefuls continue to press the industry over drug-price jumps that critics have deemed excessive.

Cost complaints have made the news for decades but in just the last month or so they've been at the forefront of new legislative discussions and election stump platforms. That's after Turing Pharmaceuticals hiked what it charges for Daraprim-an effective drug, according to industry review, that's used by cancer and AIDS patients. Turing spiked the price by 5,400% to $750 a pill from $13.50.

Amid the uproar-even Democratic presidential candidate Hillary Clinton tweeted that the "gouging" was...